Pergoveris®

Phase 3

Merck KGaA (MKKGY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Assisted Reproductive Techniques

View Full Landscape

Drug Information

Target Indication

Assisted Reproductive Techniques

Clinical Trial

NCT01297465

Last updated: 10/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/25/2007

Pergoveris

Pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (LH) and follicle-stimulating-hormone deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/l.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MKKGY

Merck KGaA

Pharmaceutical Preparations•Europe•Xetra

Related Pipeline

Recombinant human chorionic gonadotropin (r-hCG)Phase 3

Assisted Reproductive Techniques

GONAL-f®Phase 3

Infertility